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Recent genome-wide association studies have shown the importance of common genetic variation in 
mediating the risk of colorectal cancer by identifying at least 16 germline single-nucleotide 
polymorphisms (SNPs) that are significantly associated with disease incidence. To examine whether 
this common genetic variation could also play a role in disease prognosis, postdoctoral fellow 
Amanda Phipps and colleagues from the Public Health Sciences Division recently examined whether 
the 16 previously identified SNPs associated with colorectal cancer incidence were also associated 
with overall and disease-specific mortality in a sample of 2611 cases of invasive colorectal cancer 
pooled from five separate prospective cohort studies. 
In their meta-analysis of overall survival, adjusted for sex and age at diagnosis, most of the SNPs 
previously associated with risk of incident colorectal cancer showed no association with survival 
(after Bonferroni adjustment for multiple comparisons). However, a significant association was 
detected with SNP rs4939827 (18q21, SMAD7), such that each copy of the minor allele (G) was 
associated with a 16% increased risk of all-cause mortality (Hazard Ratio (HR): 1.16, 95% 
Confidence Interval (CI): 1.06-1.27; p=0.002), a finding that was similar across all five individual 
studies. Rs4939827 was also associated with poorer disease-specific survival (HR: 1.17, 95% CI: 
1.05-1.30, p=.005), although this association was only of borderline statistical significance after 
adjustment for multiple comparisons. 
Phipps and colleagues found no apparent difference in the association between rs4939827 and 
survival according to smoking status, body mass index or the use of anti-inflammatory medications. 
Adjusting for stage at diagnosis modestly attenuated the association with overall survival (HR: 1.13, 
95% CI: 1.01-1.30, p=.005), while there was a non-significant difference according to family history 
(HR: 1.01, 95% CI: 0.69-1.46 vs. HR: 1.18, 95% CI: 1.05-1.32 for patients with and without a family 
history of colorectal cancer, respectively). 
 Interestingly, the study’s findings appear contrary to previously reported associations of rs4939827 
with decreased risk of incident colorectal cancer. Because Rs4939827 is located on an intronic 
region of SMAD7, a downstream inhibitor of transforming growth factor-β1 (TGF-β1), the current 
study authors postulate that the apparent contradiction may be owed to the pleiotropic function of the 
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TGF-β1 pathway, which functions as a tumor suppressor in normal epithelium but can nevertheless 
promote metastasis in established tumors. Although the functionality of rs4939827 is currently 
unknown, it is plausible that a variant in SMAD7 that contributes to up-regulation of TGF-β1 could 
result in lower cancer risk but poorer post-diagnosis survival. 
This study provides support for the role of genetic variation in survival after a colorectal cancer 
diagnosis, specifically the minor allele in rs4939827. However, the common genetic variants most 
strongly associated with survival are likely to be distinct from those that underlie initial tumor 
development. 
Phipps AI, Newcomb PA, Garcia-Albeniz X, Hutter CM, White E, Fuchs CS, Hazra A, Ogino S, Nan 
H, Ma J, Campbell PT, Figueiredo JC, Peters U, Chan AT. (2012). Association between colorectal 
cancer susceptibility loci and survival time after diagnosis with colorectal 
cancer. Gastroenterology. 143(1):51-54.e4. 
 
Image courtesy of author 
Figure. Association between 
dose of rs4939827 minor allele 
and a) overall survival and b) 
colorectal cancer-specific 
survival by study population, 
adjusted for age at diagnosis 
and sex. HPFS=Health 
Professionals Follow-Up Study; 
NHS=Nurses’ Health Study; 
PHS=Physicians’ Health Study; 
VITAL= VITamins and Lifestyle 
Study; WHI=Women’s Health 
Initiative. 
